# 1. Financial Performance ## A. Key Figures * **Gross Revenue:** **₹2,503 Cr** (+10%) · **Net Revenue** up 7% YoY * **EBITDA:** **₹151 Cr** (+18%) · Margin expanded 128 bps to **7%** * **PAT:** **₹73 Cr** (+21%) · Margin improved 80 bps to **4.0%** * **EPS:** **₹23.7** (+21% YoY) * **JV Profit:** **₹19 Cr** (+73% YoY) ## B. Revenue Growth * **Liquor Segment Momentum:** Sales surged **42%** sequentially (March to June), driven by strong demand and production advantages, with YoY growth in the 7–12% range. * **Divergence in Profitability:** Despite robust revenue growth in liquor, **net profit declined 75%** in the March–June period, signaling margin pressure in the segment. * **Top-Line Resilience:** Revenue growth sustained across geographies, with Q1 sales rising to ₹1,805 Cr from ₹1,593 Cr YoY and up from ₹1,609 Cr sequentially. ## C. EBITDA & Margins * **Operational Leverage:** EBITDA growth outpaced revenue, aided by improved efficiency and a favorable product mix in the JV, which saw EBITDA rise **~40%**. * **Margin Volatility:** Q1 EBIT margin improved to **12%** from **5%** YoY, but declined sharply from **27%** in the prior quarter, indicating cost or mix headwinds. * **Chemicals Profitability:** Segment maintained solid **9% EBIT margin**, reflecting stable cost control and pricing power. ## D. Profit & EPS * **Earnings Expansion:** PAT growth of 21% and EPS increase to ₹7 reflect strong bottom-line leverage, supported by JV contributions and operating efficiency. * **JV Sensitivity:** Joint venture profits showed high operating leverage, with PAT growth significantly exceeding revenue gains, underscoring low incremental costs. ## E. Cash Flow & Debt * **Self-Funded Model:** All CapEx fully funded internally; future maintenance spend to be covered by **internal accruals**, with no plans for fresh equity or debt. * **Debt Management:** **₹300 Cr** loan maturity to be repaid from cash flows; total outgo of **₹325 Cr**, leaving minimal debt of **₹100–150 Cr**. * **Cost Focus:** Finance costs flagged as a key concern; management prioritizing asset utilization to offset rising interest burden. --- # 2. Segment Performance ## A. Key Figures * **Net Revenue:** ₹1,040 Cr total (+7%) · ₹342 Cr Potable Spirits (+22%) · ₹348 Cr BioFuels (+45%) * EBIT Margins: 21.1% Potable Spirits (from 17.5%) · 10.9% Chemicals (+100 bps) · 6.5% BioFuels (Q1FY26) * **Segment EBIT:** ₹72 Cr Potable Spirits · ₹33 Cr Chemicals · JV contribution of ₹19 Cr (Q1FY26) ## B. Potable Spirits * **Strong Growth & Margin Recovery:** Potable Spirits delivered robust double-digit revenue growth and a notable turnaround in EBIT margins, now at 1%, reversing prior-year contraction. * **Market Leadership & Expansion:** Firm maintains leadership in UP and Uttarakhand, with expanding presence in Delhi, driven by premiumization, cost optimization, and tetra packaging adoption. * **Strategic Momentum:** Amrut partnership is scaling efficiently, supporting stable operations and regional market penetration. ## C. BioFuels * **High-Growth Trajectory:** BioFuels achieved strong revenue expansion and established a 5% EBIT margin in Q1, signaling improved operational efficiency and scalability. * **Bacardi Collaboration Deepens:** Partnership extends beyond contract bottling to full-scale manufacturing at Kashipur, covering most of North and East India, enhancing strategic value. ## D. Chemicals * **JV-Led Turnaround:** The Clariant JV drove double-digit sales and high double-digit EBITDA growth, with Q1 contribution already exceeding full-year prior level, aided by better product mix and import leverage. * **Margin Expansion & Diversification:** Chemicals segment achieved 9% EBIT margin (up 100 bps) despite flat revenues, supported by value-added formulations and reduced reliance on commodity ethylene oxide. * **Innovation & Strategic Positioning:** Focus on long-term co-development with global players in high-potential areas like crop protection, bio-based amines, and carbon smart products reinforces shift toward differentiated, non-commodity offerings. ## E. Ennature Biopharma * **Deteriorating Fundamentals:** Ennature faced weak sales and margin pressures, with net margin contraction to **38%** from prior highs, indicating ongoing operational challenges. --- # 3. Product & Brand Performance ## A. Key Figures * **Bunty Bubli Growth:** **15% to 20%** annual growth since launch * **Product Mix:** **Millionaire case brand** status achieved by Soulmate Blue whiskey ## B. Liquor Brands * **Market Leadership:** Bunty Bubli remains the **highest-selling country liquor brand in India for three consecutive years**, driven by broad strength-category appeal and flavor differentiation in key markets like UP. * **Premium Expansion:** Strategic partnership with **Amrut** enables entry into premium spirits via royalty-based manufacturing and marketing, targeting UP, Delhi, and Uttarakhand with top-end positioning and high-quality standards. * **In-House Advantage:** Launch of **Maqintosh White and Black Label** whiskeys leverages **vertically integrated extra neutral alcohol**—a premium input also supplied to global leaders including Diageo and Pernod. * **Brand Loyalty:** Soulmate Blue exhibits **exceptional consumer loyalty**, with retail out-of-stocks leading to lost sales as customers refuse substitutes—a rare behavioral trend underscoring brand strength. ## C. Nutraceuticals * **Revenue Diversification:** Expansion into **nutraceuticals, co-branded products, and formulated portfolios** marks a strategic shift beyond API dependence to capture higher-margin branded opportunities. ## D. JV Product Mix * **Global Market Access:** Differentiated product strategy via **purity profiling** and **regulatory approvals** is enabling entry into the U.S., Europe, and Japan, with progress in branded formulations and compliance qualifications. * **Growth Levers:** Focus on **registrations, market differentiation, and branded formulations** to scale the business in developed markets. ## E. Premiumization * **Channel Ambition:** Targeting entry into the **Canteen Services Department (CSD)** as a key milestone to expand distribution reach for premium brands. --- # 4. Capacity & Manufacturing ## A. Key Figures * **Production Volume:** **200,000 cases/month** for Bacardi International ## B. Plant Utilization * **Tight Capacity Environment:** Industry operates with limited excess capacity and no significant overcapacity, supporting stable pricing dynamics amid steady demand growth. * **Regulatory Advantage:** Aseptic packaging mandated in **UP and Uttarakhand**, where the company holds a first-mover advantage in production capacity. ## C. Kashipur Facility * **Strategic Partnership:** IGL fully manages Kashipur plant operations for Bacardi with minimal Bacardi oversight, reflecting **15 years of trust and operational excellence**. * **Performance Enhancement:** Product mix improvements driven by internal initiatives and integration of **Clariant’s application know-how and product chemistry**. * **Full-Scale Production:** Facility handles end-to-end operations—including maturation, distillation, and logistics—for premium Bacardi brands like **Breezer, Carta Blanca, and Bacardi Limon**. ## D. Gorakhpur Expansion * **Long-Term Growth Driver:** Gorakhpur plant, operational since 2006, has accelerated growth over the past **seven to eight years**, particularly post-2017–2018 due to favorable state policies. ## E. GMP Certification * **Market Access Milestone:** Nutraceutical plant secured **GMP, EAR, and NSF certifications**, enabling entry into regulated, higher-value international markets. --- # 5. Supply & Feedstock ## A. Key Figures * **Cost Differential (Reliance vs. IGL EO):** **42%** peak in mid-2023 · **12–15%** current quarter (lowest in years) ## B. Ethanol Feedstock * **Diversified Feedstock Base:** Multiple government-approved feedstock sources available, including sugarcane juice, molasses variants, damaged/surplus food grains, and corn, enhancing supply resilience. ## C. Raw Material Stability * **Secure Supply Chain:** Bio-Fuel segment reports no current raw material constraints, with past logistical hiccups resolved. * **Regulated Pricing Shield:** Ethanol prices are government-administered, factoring in feedstock cost variations, with active interventions to ensure availability and prevent price volatility. * **Strategic Feedstock Evaluation:** Company is assessing alternative feedstocks and value propositions as part of long-term strategy, though details remain premature. --- # 6. Demand & Market Share ## A. Key Figures * **Market Share:** **16%** in Country Liquor segment · **24–25%** overall category share * **District-Level Dominance:** **>95%** share in nine UP districts * **Premium Segment Penetration:** **>10%** share in Delhi’s Rs. 850+ whiskey segment within a year of launch * **Paramilitary Supplier Rank:** **#4** out of **66** companies ## B. Country Liquor * **Uncontested Regional Leadership:** Maintains dominant market position in UP and Uttarakhand, underpinned by superior ENA quality and traditional blending, driving brand loyalty for **Bunty Bubli**, India’s top-selling liquor brand. * **Strategic Urban Stronghold:** Sustains long-standing, low-risk presence in Delhi via **Soulmate Blue**, a top-three brand in the state. * **Policy-Driven Volatility:** Recent state-level regulatory changes in UP and Uttarakhand triggered pre-implementation stockpiling, distorting near-term demand patterns across Q4–Q1. ## C. Vodka Segment * **Top-Tier Competitive Position:** Ranked among the **top three vodka brands** in Delhi’s crowded market of 35+ players, fueled by imported enhancers that support premiumization and retention. * **Strong Share Momentum:** Vodka segment gaining traction with sustained consumer migration and loyalty, while **Amazing Vodka** expands footprint across launch markets. * **Premiumization Tailwinds:** High double-digit growth in Rs. 850+ and Rs. 1,000+ whiskey segments reflects aspirational demand, with Maqintosh capturing significant share early in its lifecycle. ## D. Paramilitary Sales * **Rapid Institutional Penetration:** Secured all-India supply contract for **ITBP, BSF, CRPF, and SSB**, positioning IGL as a top-four national supplier within just one year of entry. * **Strategic Multiplier Effect:** Paramilitary contract enhances civil market credibility and creates a snowballing opportunity for broader commercial expansion. ## E. Export Markets * **Export Headwinds:** Thiocolchicoside exports face pressure from weak demand in **Turkey**—a key EU gateway—amid growing competition from Indian exporters with easier EU access. * **Stable Niche Demand:** Nicotine exports remain resilient despite competitive intensity. --- # 7. Risks & Margin Pressures ## A. Key Figures * **Cost Differential:** **42%** (unprecedented spike resolved) ## B. API Competition * **Margin Squeeze Intensifies:** API business faces narrowing margins on key products like thiocolchicoside and nicotine due to new entrants, excess capacity, and **lower-margin sales mix**, despite strong historical top-line growth. * **Business Model Under Scrutiny:** Ennature Biopharma’s current net margin levels resemble **trading rather than manufacturing economics**, raising questions ahead of planned demerger. * **Differentiation Strategy:** Company is focusing on impurity profiling, dossier quality, and regulatory compliance to penetrate developed markets and counter competitive pressures. ## C. Feedstock Volatility * **Margin Drivers Identified:** Bio-Fuel segment margins are exposed to ethanol pricing, grain costs (DFG), and DDGS byproduct realization, with past volatility partially mitigated by regulatory support. * **CapEx Not Translating to Leverage:** Despite major investments and operational transformation, **no operating or financial leverage** has materialized as profit growth lags behind sales expansion. ## D. Chinese Imports * **Pricing Pressure from China:** Chemical segment faces headwinds from Chinese competition in natural muscle relaxants, compounded by feedstock oversupply and new entrants. * **MEG Market Imbalance:** Green MEG margins pressured by widening spread vs. crude-based MEG, driven by lower oil prices and soft PET demand—though **long-term demand for bio-based MEG seen growing at double-digit rates**. --- # 8. Guidance & Outlook ## A. Key Figures * **Ethanol Blending Progress:** **5%** (2019–20) → **10%** (2021) → **12%** (2022–23) → **15%** (2023–24) → **19%** (2024–25) → **20%** (expected 2025–26) * **Blending Target:** **20% by 2025** (brought forward from 2030) · Exploring **25–30% by 2030** ## B. Blending Policy & Sector Momentum * **Accelerated National Adoption:** Ethanol blending is advancing rapidly, with multiple states already achieving 20% and the national program on track to meet its accelerated timeline. * **Policy Tailwinds:** Government commitment remains strong, with NITI Aayog evaluating higher mandates by 2030 to boost energy security and reduce forex outflow. * **Sector Resilience:** Biofuels viewed as a stable, long-term national initiative with robust execution, ensuring investor confidence despite short-term volatility. ## C. State Expansion & Market Access * **Cautious Geographic Rollout:** Expansion into **Kerala** marks first entry outside North India, with **two to three additional states** and **CSD** targeted this fiscal, pending profitability thresholds. * **Strategic Leadership Oversight:** Market entries require approval from **CFO, CEO, and CMD**, emphasizing disciplined growth and substantial return potential. * **Regulatory Positioning:** Ongoing efforts to secure direct approvals in high-barrier markets, leveraging completed compliance dossiers to strengthen access. ## D. Margin & Growth Outlook * **Volume Growth Ambition:** Targeting **over 150% growth** in volume and value contribution from biofuels, supported by favorable cost trends and joint venture end markets. * **Margin Expansion Levers:** Branded nutraceutical launch in